secwatch.observer — SEC 8-K summary
======================================

Issuer:     Clearside Biomedical, Inc. (CLSDQ)
CIK:        0001539029
Form:       8-K
Filed at:   2025-05-30T23:59:59+00:00
Accession:  0000950170-25-079689
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Clearside Biomedical shareholders approve doubling authorized common stock to 400M shares
--------------------------------------------------------------------------------

- Shareholders approved amendment to increase authorized common shares from 200M to 400M; 38.8M for, 10.3M against, 0.6M abstain.
- All three director nominees (Lasezkay, Shaffer, Gibney) were elected with >25M votes for.
- Advisory vote on executive compensation approved: 18.9M for, 3.4M against, 6.8M abstain.
- Ratification of Ernst & Young as auditor for FY2025 approved: 48.5M for, 1.2M against.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1539029/000095017025079689/0000950170-25-079689-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1539029/000095017025079689/clsd-20250530.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-079689

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer